BAIT
VHL
HRCA1, RCA1, VHL1, pVHL
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase
GO Process (13)
GO Function (5)
GO Component (6)
Gene Ontology Biological Process
- cell morphogenesis [NAS]
- cellular response to hypoxia [TAS]
- negative regulation of apoptotic process [NAS]
- negative regulation of cell proliferation [TAS]
- negative regulation of transcription from RNA polymerase II promoter [TAS]
- negative regulation of transcription from RNA polymerase II promoter in response to hypoxia [IDA]
- positive regulation of cell differentiation [NAS]
- positive regulation of transcription, DNA-templated [IMP]
- protein stabilization [NAS]
- protein ubiquitination [IDA, IMP]
- proteolysis [TAS]
- regulation of transcription from RNA polymerase II promoter in response to hypoxia [TAS]
- regulation of transcription, DNA-templated [IMP]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
BMPR1A
10q23del, ACVRLK3, ALK3, CD292, SKR5
bone morphogenetic protein receptor, type IA
GO Process (9)
GO Function (6)
GO Component (2)
Gene Ontology Biological Process
- BMP signaling pathway [IDA, TAS]
- endocardial cushion formation [ISS]
- immune response [IMP]
- positive regulation of SMAD protein import into nucleus [IDA]
- positive regulation of bone mineralization [IMP]
- positive regulation of osteoblast differentiation [IMP]
- positive regulation of pathway-restricted SMAD protein phosphorylation [IDA]
- protein phosphorylation [IDA]
- transforming growth factor beta receptor signaling pathway [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
- caveola [IMP]
- plasma membrane [IDA, TAS]
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors.
Exploiting cancer vulnerabilities is critical for the discovery of anticancer drugs. However, tumor suppressors cannot be directly targeted because of their loss of function. To uncover specific vulnerabilities for cells with deficiency in any given tumor suppressor(s), we performed genome-scale CRISPR loss-of-function screens using a panel of isogenic knockout cells we generated for 12 common tumor suppressors. Here, we provide ... [more]
Sci Adv Dec. 13, 2021; 8(19);eabm6638 [Pubmed: 35559673]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507) [viability (PATO:0000169)]
Additional Notes
- CRISPR GI screen
- Cell Line:HEK-293A
- Experimental Setup: Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library: TKO v3 (ADDGENE:90294)
- Significance Threshold: BAGEL (QBF_X_TSG KO>5, QBF_X_WT_Average<3, and QBF_X_TSG KO - QBF_X_WT_Max>5, where X is any gene from TKOv3 library) and DrugZ (P<0.01)
- Significance Threshold: BAGEL (QBF_X_TSG KO>5, QBF_X_WT_Average<3, and QBF_X_TSG KO - QBF_X_WT_Max>5, where X is any gene from TKOv3 library) and DrugZ (P<0.01)
Curated By
- BioGRID